Medical drug program updates

You can refer to the chart below to review changes and updates related to CarePartners of Connecticut's prior authorization and coverage program for medical drugs.

New prior authorization programs 

 

Drug/MNG

 

Plan and additional information

 

Effective date

 

Kebilidi

 

Prior authorization is now required for Kebilidi (J3590), an adeno-associated virus vector-based gene therapy indicated for the treatment of adult and pediatric patients with aromatic L-amino acid decarboxylase deficiency.

Our coverage criteria are aligned with MassHealth’s, as is the case for all gene therapies.

10/1/2025

 

Encelto

 

The ophthalmology drug Encelto (J3403) is covered with prior authorization. 

 

10/1/2025